Who Reviews Your GLP-1 Intake at Join Luma?

Medical care is provided by Arora Health and Aesthetics. Dr. Sean Arora, MD, is founder and medical director, is board-certified in family medicine and is licensed in all 50 states. Dr. Shannon Arora, MD, is Chief Medical Officer. These leadership roles identify the medical organization; they do not mean either physician personally reviews every individual intake.

A licensed clinician reviews your submitted information and makes the prescribing decision. Read the profiles of Dr. Sean Arora and Dr. Shannon Arora for background. When asking about your own care, focus on the clinician responsible for your prescription and how to send that clinician a question through the patient portal.

Your intake gives the clinician information about your current weight and height, conditions, medications, allergies, goals and prior experience with weight-management treatment. Include supplements and medicines from other prescribers, not just prescriptions related to weight. A medication that seems unrelated may still affect safe planning.

If you already use a GLP-1 medication, report its exact name, formulation, dose in milligrams and last dose date. Explain any missed doses or troublesome symptoms. A photo of a current prescription label can clarify concentration and directions when requested. Do not report only syringe units without the concentration: the same number of units can represent a different medication amount from another vial.

For adult chronic weight management, FDA-approved brand-product criteria have commonly included BMI of at least 30, or at least 27 with a weight-related condition such as hypertension, dyslipidemia or type 2 diabetes. These are clinical context for brand products, not a guarantee that a Join Luma compounded prescription is appropriate or available to every person meeting a number.

The Wegovy label and Zepbound label describe their own approved populations and indications; eligibility can depend on more than BMI and differs by indication. A clinician also considers safety, medical need and the proposed formulation. Use the BMI calculator to prepare accurate information, not to self-approve treatment or hide a condition that needs discussion.

Tell the clinician about any personal or family history of medullary thyroid carcinoma, often abbreviated MTC, or multiple endocrine neoplasia syndrome type 2, called MEN2. Wegovy and Zepbound are contraindicated in people with those histories. Do not assume every thyroid diagnosis means the same thing: provide the actual diagnosis if you know it and ask for help clarifying uncertainty.

Also disclose previous serious allergic reactions to semaglutide, tirzepatide or ingredients in a proposed formulation. Formulations may contain different additives, so include known ingredient allergies even if you tolerated another version previously. The clinician can distinguish a contraindication from an issue that requires additional review. Never omit family history because a relative’s diagnosis feels distant or because you have not personally had symptoms.

Report pregnancy, plans to become pregnant and breastfeeding before starting. Weight-loss treatment is not appropriate during pregnancy, and brand labeling includes specific pregnancy guidance. Wegovy labeling advises stopping at least two months before a planned pregnancy; that is brand-label context to discuss with your clinician, not a substitute for a personalized plan.

Zepbound labeling advises users of oral hormonal contraceptives to switch to a nonoral method or add a barrier method for four weeks after starting and for four weeks after each dose escalation. Tell the clinician about contraception so you can receive appropriate counseling. Also disclose pancreatitis, gallbladder disease, severe gastrointestinal symptoms, kidney issues, diabetes treatments and upcoming anesthesia or sedation. The significance of each depends on your situation.

The FDA explains that compounded drugs are not reviewed for safety, effectiveness or quality before marketing. A clinician should consider whether your individual needs call for a compounded preparation rather than assuming it is interchangeable with an FDA-approved product. Ask which medication and formulation are proposed and why they fit your needs.

Join Luma offers compounded semaglutide and compounded tirzepatide, including weekly injection and once-daily oral ODT formats. Evidence and instructions for FDA-approved brands should not be presented as proof of equivalent outcomes for those compounded preparations. If an oral option is proposed, ask about its specific instructions and ingredients rather than applying directions from a brand injection or tablet.

Respond to follow-up questions with accurate details and let the clinician know when you are unsure. You may need to clarify a diagnosis, medication list, treatment gap or prior reaction before a prescribing decision can be made. This guide does not promise an automatic approval or a specific turnaround time for review.

You are charged only if treatment is approved. After prescribing, follow the label and ask before changing the dose, combining therapies or restarting after a break. The FDA’s dosing-error guidance explains why concentration and measurement deserve particular care with compounded injectable semaglutide. See how the full Join Luma process works for what follows the medical decision.

Support is available 24/7 at support@joinluma.com or through the patient portal; most inquiries receive a reply within 1–2 hours. That is a typical support response window, not a guarantee of clinician review or an emergency service. Ask support to help route medical questions to your clinician rather than treating a billing reply as dosing authorization.

A useful question identifies the medication, current dose, last dose date, symptom or concern, and the decision you need help making. For example, ask whether a missed-dose interval changes your next prescribed dose instead of asking only whether the plan is still active. Billing status and clinical readiness are different issues.

Seek urgent care for severe abdominal pain, signs of pancreatitis, significant dehydration, or a serious allergic reaction; call 911 for a life-threatening emergency. Do not wait for a portal reply in an emergency. For nonurgent nausea, constipation, appetite changes or uncertainty about the next dose, contact your clinician for a plan tailored to your symptoms.